Your browser doesn't support javascript.
loading
Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis.
Abdelwahab, Omar Ahmed; Mechi, Ahmed; Gahlan, Shereen; Hamadein, Fatima-Elzahraa; Kadhim, Hallas; Ismail, Doaa; Soliman, Youssef; El-Samahy, Mohamed.
Afiliação
  • Abdelwahab OA; Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt. omarabdelwahab.216@azhar.edu.eg.
  • Mechi A; Medical Research Group of Egypt, Cairo, Egypt. omarabdelwahab.216@azhar.edu.eg.
  • Gahlan S; Medical Research Group of Egypt, Cairo, Egypt.
  • Hamadein FE; Internal Medicine Department, Medicine College, University of Kufa, Najaf, Iraq.
  • Kadhim H; Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt.
  • Ismail D; Medical Research Group of Egypt, Cairo, Egypt.
  • Soliman Y; Faculty of Medicine, University of Gezira, Wad Madani, Sudan.
  • El-Samahy M; Medical Research Group of Egypt, Cairo, Egypt.
Clin Rheumatol ; 43(2): 621-632, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37981614
ABSTRACT

BACKGROUND:

Immune thrombocytopenic purpura (ITP) is a challenging disease in its presentation and management as it may cause life-threatening hemorrhaging in vital organs and may resist several lines of treatment. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of mycophenolate mofetil (MMF) in treating patients with ITP.

METHODS:

We systematically searched four electronic databases (PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials) from inception until 10 October 2022. We included all clinical trials, either controlled or single arm, and prospective and retrospective observational studies that evaluate the efficacy and safety of MMF in patients with ITP. We assessed the risk of bias using three tools (ROBINS-I, Cochrane ROB-2, and NIH), each for eligible study design.

RESULTS:

Nine studies were included in this meta-analysis, with a total of 411 patients with ITP. We found that MMF demonstrated an overall response rate of (62.09%; 95% CI = [43.29 to 77.84]) and the complete response rate was (46.75%; 95% CI = [24.84 to 69.99]). The overall proportion of adverse events was (12%; 95% CI = [6 to 24]). After the sensitivity analysis, the overall response rate became 50%; 95% CI = [38 to 63]) and the complete response rate became (32%; 95% CI = [24 to 42]). However, MMF did not appear to affect white blood cell counts or hemoglobin levels significantly.

CONCLUSION:

This systematic review and meta-analysis demonstrate that MMF appears to be an effective and relatively safe treatment option for patients with ITP when combined with steroids and even in those who have not responded to standard therapies (steroid-resistant cases). Further research with well-designed studies is warranted to better understand the factors influencing treatment response and to refine the use of MMF in the management of ITP. An interactive version of our analysis can be accessed from here https//databoard.shinyapps.io/mycophenolate_meta/.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Ácido Micofenólico Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Clin Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Ácido Micofenólico Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Clin Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Egito